EMC Capital Management Acquires 946 Shares of Moderna, Inc. (NASDAQ:MRNA)

EMC Capital Management raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 311.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,250 shares of the company’s stock after buying an additional 946 shares during the period. EMC Capital Management’s holdings in Moderna were worth $52,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. State Street Corp boosted its stake in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the last quarter. Wellington Management Group LLP grew its holdings in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after buying an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on MRNA shares. UBS Group reduced their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Leerink Partners decreased their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Wolfe Research initiated coverage on Moderna in a research note on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price on the stock. The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $99.00 to $51.00 in a research report on Wednesday. Finally, Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $67.26.

Moderna Stock Performance

Shares of MRNA opened at $39.42 on Friday. Moderna, Inc. has a 12-month low of $31.94 and a 12-month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market cap of $15.17 billion, a PE ratio of -6.77 and a beta of 1.60. The stock has a 50-day moving average price of $40.89 and a 200-day moving average price of $61.32.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.39) EPS. As a group, equities analysts forecast that Moderna, Inc. will post -9.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 2,664 shares of company stock worth $115,210. Corporate insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.